Objective: To evaluate the results of posterior sub-tenon triamcinolone acetonide in patients of refractory macular oedema suffering with retinal vascular disorders.
Methods: This quasi-experimental study was conducted at Layton Rahmatulla Benevolent Trust, Lahore, Pakistan, from October 2014 to March 2015, and comprised eyes of patients with refractory macular oedema. The central macular thickness of all patients was determined with ocular coherence tomography before giving injection of 40mg/ml posterior sub-tenon triamcinolone acetonide. After the injection, central macular thickness of each eye was measured in follow-ups at 1st week, 1st month and 2nd month with ocular coherence tomography.
Results: Of the 40 participants, 26(65%) were men and 14(35%) women. The mean age was 61.80±7.20 years. The mean central macular thickness before injection was 488.70±34.93, while it was 337.60±146 after 1st week of injection, 420.60 ± 76.13 after 1st month and 477.98±72.30 after two months. Comparisons of central macular thickness at various follow-ups showed a significant difference from the baseline to the last follow-up (p<0.001). Moreover, 4(14%) subjects showed consistent improvement in central macular thickness.
Conclusions: Posterior sub-tenon triamcinolone acetonide can be considered a short-term treatment option in cases of refractory macular oedema.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Subthreshold nanosecond laser therapy for chronic central serous chorioretinopathy: A prospective study.
J Fr Ophtalmol
January 2025
Department of Ophthalmology, Saarland University Medical Center UKS, Homburg/Saar, Germany.
Purpose: To investigate the morphologic and functional outcomes of nanosecond subthreshold (ST) laser treatment for patients with chronic central serous chorioretinopathy (CSC).
Methods: In this prospective study, 44 patients were treated with the ST nanosecond laser with a follow-up period of 12 months. All target variables were measured at 1, 3, 6 and 12 months after the first laser treatment.
Predictors of Peripheral Retinal Non-Perfusion in Clinically Significant Diabetic Macular Edema.
J Clin Med
December 2024
Lions Eye Institute, Perth, WA 6009, Australia.
Diabetic macular edema (DME) is a significant cause of vision loss. The development of peripheral non-perfusion (PNP) might be associated with the natural course, severity, and treatment of DME. The present study seeks to understand the predictive power of central macular changes and clinico-demographic features for PNP in patients with clinically significant DME.
View Article and Find Full Text PDFLong-Term Effects of COVID-19 on Optic Disc and Retinal Microvasculature Assessed by Optical Coherence Tomography Angiography.
Diagnostics (Basel)
January 2025
Department of Ophthalmology, Haseki Training and Research Hospital, 34096 Istanbul, Turkey.
: To evaluate the long-term effects of coronavirus disease (COVID-19) on optic disc and macular microvasculature. : 40 post-COVID-19 and 40 healthy subjects were included. Optical coherence tomography angiography (OCTA) was performed for all subjects at the first visit and repeated in the fourth and twelfth months.
View Article and Find Full Text PDFFunctional and Anatomical Outcomes of Pars Plana Vitrectomy for Lamellar Macular Hole: Long-Term Follow-Up.
Diagnostics (Basel)
December 2024
Eye Clinic, Neuromuscular and Sense Organs Department, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy.
Background: To investigate functional and anatomical outcomes after pars plana vitrectomy (PPV) for lamellar macular hole (LMH) with a long-term follow-up.
Methods: An interventional study on 14 patients (16 eyes) with LMH was conducted. The inclusion criteria included a minimum 36-month follow-up after PPV.
Outcomes of intravitreal dexamethasone implant (Ozurdex) in patients with post-surgical macular edema - a real-world scenario.
Int J Retina Vitreous
January 2025
Ophthal - Hospital Especializado, São Paulo, SP, Brazil.
Background: Clinically significant macular edema (CME) is the leading cause of visual loss after ophthalmologic surgery due to the release of inflammatory mediators promoted by the procedures. We aimed to evaluate the outcomes of intravitreal Ozurdex (700 µg dexamethasone) implants as a primary therapeutical option for post-surgical macular edema cases.
Methods: Patients with post-surgical macular edema diagnosed by optical coherence tomography (Cirrus SD-OCT) and treated with Ozudex were selected for the current study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!